Biotechnology, Pharmaceuticals, and Research by Biogen
Biogen New Ventures takes part in Series A funding for Estuary Biotherapeutics: Can BIIB break above $240.99?
Biogen New Ventures is backing gene therapy startup Estuary Biotherapeutics through its participation in the company's Series A financing. Shares are up 1% on the day at $235.35.Biogen New ...
Biogen stock edges lower despite RayThera partnership
Biogen announced the completion of its acquisition of RayThera Inc on July 13, 2026. Meanwhile, the stock edges lower on the day, trading at $206.28.Biogen announced the completion of its ...
Biogen stock trades up toward $207.56 with buyers in control above MA-20 and Kijun support
Biogen said it will attend #GlomConHawaii 2026 to share information about its approach to kidney diseases driven by complement and immune mechanisms. At the same time, Biogen stock is up 2.8% on ...
Biogen stock jumps 2.73 percent as Biogen kicks off Q2 2026 earnings webcast
Biogen is set to begin its second-quarter 2026 earnings call webcast at 8:30AM ET.The company invited listeners to join the webcast through a provided link. Details are being ...
Biogen stock extends rally above $205 with bullish momentum and limited downside risk
Biogen announced its second quarter results, showing progress toward its goal of sustainable revenue growth.The company provided a link to read more about its performance. Forward-looking ...
Biogen stock edges higher to $198.67 after RayThera acquisition news, Biogen announces
Biogen announced an agreement to acquire RayThera Inc. on Thursday.Biogen stated that with this deal, it aims to add multiple immunology assets to its portfolio. The company expects these ...
Biogen stock jumps 3.78% as FDA grants breakthrough therapy status for SMA, biogen announces
Biogen said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for its investigational therapy for spinal muscular atrophy.Biogen described the development as an ...
Biogen stock slides 1.77 percent as Biogen announces kidney data presentations in Europe and US
Biogen announced it will share 14 abstracts from its nephrology portfolio at the European Renal Association and American Transplant Congresses. The company provided the update on its upcoming ...
Biogen stock drops 1.61 percent as company promotes CD-38 therapy research at ERA Congress
Biogen is attending the ERA Kidney Congress to share data on its investigational therapy targeting CD-38 cells in immune-mediated diseases.The company invited attendees to join and learn about its ...
Biogen stock falls 2.51 percent as company promotes lupus research at EULAR 2026 event
Biogen announced it is joining the global rheumatology community at an upcoming @eular_org event to share its latest research on systemic lupus erythematosus.The company invited attendees to find ...
